Eyebright Medical Technology (Beijing) Co (688050) Fair Value & Analysis
Healthcare · CN · Market cap 7.8B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from ¥30.19 to ¥24.37 (−19.3%) since Jun 24, 2026. Share price +2.0% over the past month.
A solid business, but screening 41% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥30.74). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥36.26 – ¥384.94 · fair‑value band ¥18.00 – ¥30.74 · the ¥41.06 price screens above the ¥24.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Eyebright Medical Technology (Beijing) Co (688050) currently trades at ¥41.06, while our model-based Fair Value estimate is ¥24.37, implying the stock looks roughly 40.7% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Eyebright Medical Technology (Beijing) Co generated revenue of 1.5B CNY at a net margin of 17.4%. Revenue grew 11.5% year over year. It earns a return on equity of 8.2%. Net debt stands at 215M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥18.00 (bear case) to ¥30.74 (bull case); at ¥41.06, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 51% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -41%, 688050 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥63.75) versus Dividend Discount (¥6.99). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally.
Full company description
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for ophthalmic surgery, refractive error correction, and optometry consumption. Eyebright Medical Technology (Beijing) Co., Ltd. was founded in 2010 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Eyebright Medical Technology (Beijing) Co reported revenue of ¥1.5B in FY2025 versus ¥433M in FY2021, a compound +36.0%/yr. Reported net income was ¥265M in FY2025, compounding +11.6%/yr from FY2021.
688050 screens 41% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Eyebright Medical Technology (Beijing) Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Eyebright Medical Technology (Beijing) Co (688050) overvalued or undervalued?
What is the fair value of 688050?
What is the quality score of 688050?
What is the revenue of Eyebright Medical Technology (Beijing) Co (688050)?
What is the net profit margin of 688050?
Does Eyebright Medical Technology (Beijing) Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Eyebright Medical Technology (Beijing) Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.